AKT1 and lung carcinoma: In addition, it has been found that the PI3K/AKT/mTOR signaling pathway offers great possibilities for the treatment of lung cancer; however, targeted therapy acting on the PI3K/AKT/mTOR pathway may cause many side effects and deficiencies due to acquired drug resistance [6].